摘要
目的探讨肝移植及围手术期辅助性化疗治疗肝细胞癌合并大血管侵犯的临床应用价值。方法回顾性分析2004年7月至2007年1月期间我中心收治的8例施行肝移植的肝细胞癌合并大血管侵犯患者的临床资料和随访数据,围手术期以希罗达为主进行化疗。结果围手术期死亡1例(术后第4d死于多器官功能衰竭)。余7例患者术后均获随访:1例于术后第54d死于颅内出血。5例于术后0.5～2年肿瘤复发,其中3例分别于术后9、10和16个月死亡;1例于术后1年发现肿瘤复发,放弃治疗2个月后死亡;另1例则已带瘤生存32个月仍存活。1例则无瘤生存达半年。本组患者生存时间4d～32个月,平均329.8d,生存6个月和1年者分别为6/8和3/8。结论术前存在大血管侵犯的肝癌患者,行肝移植可能仍会取得良好疗效,但需结合围手术期辅助性化疗。
Objective To evaluate the clinical effect and application value of orthotopic liver transplantation （OLT） on hepatocellular carcinoma （HCC） with macro-vascular invasion, Methods The clinical and follow-up data of 8 HCC patients with macro-vascular invasion performed OLT from July 2004 to January 2007 were retrospectively analyzed. Xeloda was the main drug of chemotherapy in perioperative period. Results One patient died of multiple organ failure on day 4 after operation. Seven patients were followed up： 1 case died of intracranial hemorrhage on day 54 after operation. The tumor recurred between 0. 5-2 years after operation in 5 patients, among these patients, 3 cases died at 9th, 10th and 16th month respectively, 1 case recurred at 1 year, and 1 case survived 32 months with tumor. One patient survived 0.5-year with tumor-free. The survival time of these patients was 4 days to 32 months. The median survival time was 329.8 days. The 6-month and 1-year cumulative survival ratio were 6/8 and 3/8, respectively. Conclusion OLT may be an effective treatment method for HCC patients with macro-vascular invasion when adjuvant chemotherapy in perioperation is combined.
出处
《中国普外基础与临床杂志》
CAS
2008年第7期484-486,共3页
Chinese Journal of Bases and Clinics In General Surgery
关键词
肝细胞癌
大血管侵犯
肝移植
Hepatocellular carcinoma Macro-vascular invasion Liver transplantation
